FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Brad Spiller

Research Profile

Chemicals & Drugs

Physiology

Complement Activation

Anatomy

Living Beings

Concepts & Ideas

Protein Structure, Tertiary

Co-author Network

Publications

TOP 3
Martha Triantafilou; Ali F Aboklaish; Benjamin De Glanville; Sailesh Kotecha; O Brad Spiller; Kathy Triantafilou
Synergic Activation of Toll-Like Receptor (TLR) 2/6 and 9 in Response to Ureaplasma parvum & urealyticum in Human Amniotic Epithelial Cells.
Sandra Pinkert; O Brad Spiller; Heinz Zeichhardt; Andrea Dörner; Karin Klingel; Vanessa Lindig; Henry Fechner
Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.
M L Beeton; N C Maxwell; P L Davies; D Nuttall; Eamon P McGreal; M Chakraborty; O Brad Spiller; Sailesh Kotecha
Role of pulmonary infection in the development of chronic lung disease of prematurity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Brad Spiller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Martha Triantafilou; Ali F Aboklaish; Benjamin De Glanville; Sailesh Kotecha; O Brad Spiller; Kathy Triantafilou
Synergic Activation of Toll-Like Receptor (TLR) 2/6 and 9 in Response to Ureaplasma parvum & urealyticum in Human Amniotic Epithelial Cells.
PloS one 2013;8(4):e61199.
2011: Sandra Pinkert; O Brad Spiller; Heinz Zeichhardt; Andrea Dörner; Karin Klingel; Vanessa Lindig; Henry Fechner
Virus-host coevolution in a persistently coxsackievirus B3-infected cardiomyocyte cell line.
Journal of virology 2011;85(24):13409-19.
2011: M L Beeton; N C Maxwell; P L Davies; D Nuttall; Eamon P McGreal; M Chakraborty; O Brad Spiller; Sailesh Kotecha
Role of pulmonary infection in the development of chronic lung disease of prematurity.
The European respiratory journal : official journal of the European Society for Clinical Respiratory Physiology 2011;37(6):1424-30.
2010: Philip L Davies; O Brad Spiller; Michael L Beeton; Nicola C Maxwell; Eileen Remold-O'Donnell; Sailesh Kotecha
Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity.
Thorax 2010;65(3):246-51.
2009: Sandra Pinkert; Dirk Westermann; Xiaomin Wang; Karin Klingel; Andrea Dörner; Konstantinos Savvatis; Tobias Grössl; Stefanie Krohn; Carsten Tschöpe; Heinz Zeichhardt; Katja Kotsch; Kerstin Weitmann; Wolfgang Hoffmann; Heinz-Peter Schultheiss; O Brad Spiller; Wolfgang Poller; Henry Fechner
Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor.
Circulation 2009;120(23):2358-66.
2009: Michael L Beeton; Victoria J Chalker; Sailesh Kotecha; O Brad Spiller
Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism.
The Journal of antimicrobial chemotherapy 2009;64(3):529-38.
2009: Michael L Beeton; Victoria J Chalker; Nicola C Maxwell; Sailesh Kotecha; O Brad Spiller
Concurrent titration and determination of antibiotic resistance in ureaplasma species with identification of novel point mutations in genes associated with resistance.
Antimicrobial agents and chemotherapy 2009;53(5):2020-7.
2009: S R Wall; D Wat; O Brad Spiller; Colin M Gelder; S Kotecha; I J M Doull
The viral aetiology of croup and recurrent croup.
Archives of disease in childhood 2009;94(5):359-60.
2009: Marcin Okroj; Linda Mark; Anna Stokowska; Scott W Wong; Nicola Rose; David J Blackbourn; Bruno Villoutreix; O Brad Spiller; Anna Blom
Characterization of the complement inhibitory function of rhesus rhadinovirus complement control protein (RCP).
The Journal of biological chemistry 2009;284(1):505-14.
2008: Philip L Davies; Nicola C Maxwell; Sailesh Kotecha; O Brad Spiller
Monoclonal anti-neutrophil elastase antibody characterisation: ability to block function, detect free versus serpin-complexed enzyme and stain intracellular granules.
Journal of immunological methods 2008;336(2):175-82.
2008: Nadine Griesche; Dimitrios Zikos; Peter Witkowski; Andreas Nitsche; Heinz Ellerbrok; O Brad Spiller; Georg Pauli; Barbara Biere
Growth characteristics of human adenoviruses on porcine cell lines.
Virology 2008;373(2):400-10.
2008: Linda Mark; David G Proctor; David J Blackbourn; Anna Blom; O Brad Spiller
Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies.
Immunology 2008;123(2):228-38.
2007: Brian J Willett; Elizabeth L McMonagle; Nicola Logan; O Brad Spiller; Pascal Schneider; Margaret J Hosie
Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand.
Journal of virology 2007;81(18):9665-79.
2007: Linda Mark; O Brad Spiller; Marcin Okroj; Simon Chanas; Jim A Aitken; Scott W Wong; Blossom Damania; Anna Blom; David J Blackbourn
Molecular characterization of the rhesus rhadinovirus (RRV) ORF4 gene and the RRV complement control protein it encodes.
Journal of virology 2007;81(8):4166-76.
2007: Anna Blom; Linda Mark; O Brad Spiller
Viral heparin-binding complement inhibitors--a recurring theme.
Advances in experimental medicine and biology 2007;598():105-25.
2007: Linda Mark; O Brad Spiller; Bruno Villoutreix; Anna Blom
Kaposi's sarcoma-associated herpes virus complement control protein: KCP--complement inhibition and more.
Molecular immunology 2007;44(1-3):11-22.
2006: O Brad Spiller; Linda Mark; Clare E Blue; David G Proctor; J A Aitken; Anna Blom; David J Blackbourn
Dissecting the regions of virion-associated Kaposi's sarcoma-associated herpesvirus complement control protein required for complement regulation and cell binding.
Journal of virology 2006;80(8):4068-78.
2006: Linda Mark; Wen H Lee; O Brad Spiller; Bruno Villoutreix; Anna Blom
The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1-2.
Molecular immunology 2006;43(10):1665-75.
2005: Ian G Goodfellow; David J Evans; Anna Blom; David Kerrigan; J Scott Miners; B Paul Morgan; O Brad Spiller
Inhibition of coxsackie B virus infection by soluble forms of its receptors: binding affinities, altered particle formation, and competition with cellular receptors.
Journal of virology 2005;79(18):12016-24.
2005: Ciarán Richardson; Paul Brennan; Martin Powell; Stuart Prince; Yun-Hsiang Chen; O Brad Spiller; Martin Rowe
Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie-adenovirus receptor and alphavbeta5 integrin expression.
The Journal of general virology 2005;86(Pt 6):1669-79.
2005: Miguel A Jimenez-Clavero; Estela Escribano-Romero; Victoria Ley; O Brad Spiller
More recent swine vesicular disease virus isolates retain binding to coxsackie-adenovirus receptor, but have lost the ability to bind human decay-accelerating factor (CD55).
The Journal of general virology 2005;86(Pt 5):1369-77.
2004: Suzanne E Myers; Laurie Brewer; Daniel P Shaw; Wallace H Greene; Brenda C Love; Bernhard Hering; O Brad Spiller; M Kariuki Njenga
Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor.
Xenotransplantation 2004;11(6):536-46.
2004: Linda Mark; Wen H Lee; O Brad Spiller; David G Proctor; David J Blackbourn; Bruno Villoutreix; Anna Blom
The Kaposi's sarcoma-associated herpesvirus complement control protein mimics human molecular mechanisms for inhibition of the complement system.
The Journal of biological chemistry 2004;279(43):45093-101.
2004: Sylvie Hudault; O Brad Spiller; B Paul Morgan; Alain L Servin
Human diffusely adhering Escherichia coli expressing Afa/Dr adhesins that use human CD55 (decay-accelerating factor) as a receptor does not bind the rodent and pig analogues of CD55.
Infection and immunity 2004;72(8):4859-63.
2004: Bobby Yanagawa; O Brad Spiller; David G Proctor; Jonathan C Choy; Honglin Luo; Huifang M Zhang; Agripina Suarez; Decheng Yang; Bruce M McManus
Soluble recombinant coxsackievirus and adenovirus receptor abrogates coxsackievirus b3-mediated pancreatitis and myocarditis in mice.
The Journal of infectious diseases 2004;189(8):1431-9.
2004: Clare E Blue; O Brad Spiller; David J Blackbourn
The relevance of complement to virus biology.
Virology 2004;319(2):176-84.
2003: Pamela Williams; Yasmin Chaudhry; Ian G Goodfellow; Jason Billington; Robert Powell; O Brad Spiller; David J Evans; Susan M Lea
Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A.
The Journal of biological chemistry 2003;278(12):10691-6.
2003: O Brad Spiller; David J Blackbourn; Linda Mark; David G Proctor; Anna Blom
Functional activity of the complement regulator encoded by Kaposi's sarcoma-associated herpesvirus.
The Journal of biological chemistry 2003;278(11):9283-9.
2003: Bobby Yanagawa; O Brad Spiller; Jonathan C Choy; Honglin Luo; Paul Cheung; Huifang M Zhang; Ian G Goodfellow; David J Evans; Agripina Suarez; Decheng Yang; Bruce M McManus
Coxsackievirus B3-associated myocardial pathology and viral load reduced by recombinant soluble human decay-accelerating factor in mice.
Laboratory investigation; a journal of technical methods and pathology 2003;83(1):75-85.
2003: O Brad Spiller; Mairi Robinson; Elizabeth O'Donnell; Steven G Milligan; B Paul Morgan; Andrew J Davison; David J Blackbourn
Complement regulation by Kaposi's sarcoma-associated herpesvirus ORF4 protein.
Journal of virology 2003;77(1):592-9.
2002: Lihua Bao; O Brad Spiller; Patricia L St John; Mark Haas; Bradley K Hack; Guohui Ren; Patrick N Cunningham; Mona Doshi; Dale R Abrahamson; B Paul Morgan; Richard J Quigg
Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes.
Kidney international 2002;62(6):2010-21.
2002: S Melanie Hanna; O Brad Spiller; Stuart M Linton; Richard J Mead; B Paul Morgan
Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement.
European journal of immunology 2002;32(2):502-9.
2002: O Brad Spiller; Ian G Goodfellow; David J Evans; Stewart J Hinchliffe; B Paul Morgan
Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF.
The Journal of general virology 2002;83(Pt 1):45-52.
2000: O Brad Spiller; Olga Criado-García; Santiago Rodríguez de Córdoba; B Paul Morgan
Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack.
Clinical and experimental immunology 2000;121(2):234-41.
2000: Claire L Harris; O Brad Spiller; B Paul Morgan
Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.
Immunology 2000;100(4):462-70.
2000: Ian G Goodfellow; RM Powell; T Ward; O Brad Spiller; Jeffrey W Almond; David J Evans
Echovirus infection of rhabdomyosarcoma cells is inhibited by antiserum to the complement control protein CD59.
The Journal of general virology 2000;81(Pt 5):1393-401.
2000: O Brad Spiller
Measurement of C3 fragment deposition on cells.
Methods in molecular biology (Clifton, N.J.) 2000;150():131-7.
2000: O Brad Spiller
Measurement of complement lysis of nucleated cells.
Methods in molecular biology (Clifton, N.J.) 2000;150():73-81.
2000: O Brad Spiller; Ian G Goodfellow; David J Evans; Jeffrey W Almond; B Paul Morgan
Echoviruses and coxsackie B viruses that use human decay-accelerating factor (DAF) as a receptor do not bind the rodent analogues of DAF.
The Journal of infectious diseases 2000;181(1):340-3.
1999: Y McGrath; Gavin W G Wilkinson; O Brad Spiller; B Paul Morgan
Development of adenovirus vectors encoding rat complement regulators for use in therapy in rodent models of inflammatory diseases.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(12):6834-40.
1999: O Brad Spiller; S Melanie Hanna; B Paul Morgan
Tissue distribution of the rat analogue of decay-accelerating factor.
Immunology 1999;97(3):374-84.
1999: O Brad Spiller; Claire L Harris; B Paul Morgan
Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells.
Journal of immunological methods 1999;224(1-2):51-60.
1998: O Brad Spiller; B Paul Morgan
Antibody-independent activation of the classical complement pathway by cytomegalovirus-infected fibroblasts.
The Journal of infectious diseases 1998;178(6):1597-603.
1998: Stewart J Hinchliffe; O Brad Spiller; Neil K Rushmere; B Paul Morgan
Molecular cloning and functional characterization of the rat analogue of human decay-accelerating factor (CD55).
Journal of immunology (Baltimore, Md. : 1950) 1998;161(10):5695-703.
1997: O Brad Spiller; Leszek K Borysiewicz; B Paul Morgan
Development of a model for cytomegalovirus infection of oligodendrocytes.
The Journal of general virology 1997;78 ( Pt 12)():3349-56.
1997: O Brad Spiller; S Melanie Hanna; Dana V Devine; F Tufaro
Neutralization of cytomegalovirus virions: the role of complement.
The Journal of infectious diseases 1997;176(2):339-47.
1996: O Brad Spiller; G Moretto; S U Kim; B Paul Morgan; Dana V Devine
Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression.
Journal of neuroimmunology 1996;71(1-2):97-106.
1996: O Brad Spiller; B Paul Morgan; F Tufaro; Dana V Devine
Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells.
European journal of immunology 1996;26(7):1532-8.